Relmas
Generic Name
Relugolix
Manufacturer
Renata Limited
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| relmas 10 mg tablet | ৳ 8.00 | ৳ 80.00 |
Description
Overview of the medicine
Relmas (Relugolix) is a non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist used for the treatment of uterine fibroids, endometriosis, and advanced prostate cancer. It works by inhibiting the release of gonadotropins, thereby reducing estrogen and testosterone levels.
Uses & Indications
Dosage
Adults
For uterine fibroids/endometriosis: typically 40 mg once daily (often in combination). For prostate cancer: 120 mg once daily.
Elderly
No specific dose adjustment required based on age alone. Monitor for age-related renal/hepatic impairment.
Renal_impairment
Mild to moderate renal impairment: No dose adjustment. Severe renal impairment: Consider dose reduction.
How to Take
Take orally once daily with or without food. Swallow the tablet whole.
Mechanism of Action
Relugolix selectively binds to and antagonizes the GnRH receptors in the anterior pituitary gland, which reduces the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This suppression of gonadotropins leads to a decrease in ovarian estrogen and progesterone production in females and testicular testosterone production in males.
Pharmacokinetics
Onset
Hormone suppression typically starts within days to weeks.
Excretion
Mainly excreted via feces (approximately 81%), with a smaller portion excreted via urine (approximately 19%).
Half life
Approximately 25-60 hours.
Absorption
Rapidly absorbed after oral administration, peak plasma concentrations reached within 1-2 hours.
Metabolism
Primarily metabolized by CYP3A4, with minor contributions from other CYP enzymes.
Side Effects
Contraindications
- Known hypersensitivity to Relugolix or any components
- Undiagnosed abnormal uterine bleeding
- Pregnancy
- Severe hepatic impairment
Drug Interactions
P-gp inhibitors
May increase Relugolix concentrations. Co-administration generally not recommended or requires dose adjustment.
Strong CYP3A inducers
May decrease Relugolix concentrations, reducing efficacy.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Limited experience with overdose. In case of suspected overdose, provide supportive care and monitor for adverse effects.
Pregnancy & Lactation
Contraindicated in pregnancy due to potential harm to the fetus. It is not known if Relugolix is excreted in human milk; breastfeeding is not recommended.
Side Effects
Contraindications
- Known hypersensitivity to Relugolix or any components
- Undiagnosed abnormal uterine bleeding
- Pregnancy
- Severe hepatic impairment
Drug Interactions
P-gp inhibitors
May increase Relugolix concentrations. Co-administration generally not recommended or requires dose adjustment.
Strong CYP3A inducers
May decrease Relugolix concentrations, reducing efficacy.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Limited experience with overdose. In case of suspected overdose, provide supportive care and monitor for adverse effects.
Pregnancy & Lactation
Contraindicated in pregnancy due to potential harm to the fetus. It is not known if Relugolix is excreted in human milk; breastfeeding is not recommended.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24-36 months from manufacturing date.
Availability
Available in pharmacies nationwide in Bangladesh
Approval Status
Approved by FDA (USA) and DGDA (Bangladesh)
Patent Status
Under patent protection
Clinical Trials
Relugolix has undergone multiple Phase 3 clinical trials, including LIBERTY 1, LIBERTY 2 (for fibroids), SPIRIT 1, SPIRIT 2 (for endometriosis), and HERO (for prostate cancer), demonstrating efficacy and safety.
Lab Monitoring
- Liver function tests (baseline and periodically)
- Bone mineral density (for long-term use)
- Pregnancy test (before starting and periodically)
Doctor Notes
- Counsel patients on potential bone density loss and menopausal symptoms. Consider DEXA scan for long-term therapy. Monitor LFTs periodically.
- Ensure patients understand contraception requirements, as Relugolix is contraindicated in pregnancy.
Patient Guidelines
- Take the medicine at the same time each day.
- Do not stop treatment abruptly without consulting your doctor.
- Inform your doctor about all other medications you are taking, including herbal supplements.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular dosing schedule. Do not take two doses at once.
Driving Precautions
Relugolix is not expected to affect the ability to drive or operate machinery. However, if you experience dizziness or fatigue, avoid such activities.
Lifestyle Advice
- Maintain adequate calcium and vitamin D intake for bone health.
- Engage in regular weight-bearing exercise.
- Avoid smoking and excessive alcohol consumption.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Relmas Brand
Other medicines available under the same brand name
